Skip to main content
NCBI home page
Biochemical Journal logoLink to Biochemical Journal
. 2001 May 15;356(Pt 1):71–75. doi: 10.1042/0264-6021:3560071

Role of glycine-534 and glycine-1179 of human multidrug resistance protein (MDR1) in drug-mediated control of ATP hydrolysis.

G Szakács 1, C Ozvegy 1, E Bakos 1, B Sarkadi 1, A Váradi 1
PMCID: PMC1221813  PMID: 11336637

Abstract

The human multidrug resistance protein (MDR1) (P-glycoprotein), a member of the ATP-binding cassette (ABC) family, causes multidrug resistance by an active transport mechanism, which keeps the intracellular level of hydrophobic compounds below a cell-killing threshold. Human MDR1 variants with mutations affecting a conserved glycine residue within the ABC signature of either or both ABC units (G534D, G534V, G1179D and G534D/G1179D) were expressed and characterized in Spodoptera frugiperda (Sf9) cell membranes. These mutations caused a loss of measurable ATPase activity but still allowed ATP binding and the formation of a transition-state intermediate (nucleotide trapping). In contrast with the wild-type protein, in which substrate drugs accelerate nucleotide trapping, in the ABC signature mutants nucleotide trapping was inhibited by MDR1-substrate drugs, suggesting a miscommunication between the drug-binding site(s) and the catalytic domains. Equivalent mutations of the two catalytic sites resulted in a similar effect, indicating the functional equivalence of the two sites. On the basis of these results and recent structural information on an ABC-ABC dimer [Hopfner, Karcher, Shin, Craig, Arthur, Carney and Tainer (2000) Cell 101, 789-800], we propose a key role of these glycine residues in the interdomain communication regulating drug-induced ATP hydrolysis.

Full Text

The Full Text of this article is available as a PDF (154.7 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Anderson M. P., Welsh M. J. Regulation by ATP and ADP of CFTR chloride channels that contain mutant nucleotide-binding domains. Science. 1992 Sep 18;257(5077):1701–1704. doi: 10.1126/science.1382316. [DOI] [PubMed] [Google Scholar]
  2. Bakos E., Klein I., Welker E., Szabó K., Müller M., Sarkadi B., Váradi A. Characterization of the human multidrug resistance protein containing mutations in the ATP-binding cassette signature region. Biochem J. 1997 May 1;323(Pt 3):777–783. doi: 10.1042/bj3230777. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Berkower C., Michaelis S. Mutational analysis of the yeast a-factor transporter STE6, a member of the ATP binding cassette (ABC) protein superfamily. EMBO J. 1991 Dec;10(12):3777–3785. doi: 10.1002/j.1460-2075.1991.tb04947.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Bruggemann E. P., Currier S. J., Gottesman M. M., Pastan I. Characterization of the azidopine and vinblastine binding site of P-glycoprotein. J Biol Chem. 1992 Oct 15;267(29):21020–21026. [PubMed] [Google Scholar]
  5. Georges E., Zhang J. T., Ling V. Modulation of ATP and drug binding by monoclonal antibodies against P-glycoprotein. J Cell Physiol. 1991 Sep;148(3):479–484. doi: 10.1002/jcp.1041480321. [DOI] [PubMed] [Google Scholar]
  6. Gottesman M. M., Pastan I. Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu Rev Biochem. 1993;62:385–427. doi: 10.1146/annurev.bi.62.070193.002125. [DOI] [PubMed] [Google Scholar]
  7. Higgins C. F. ABC transporters: from microorganisms to man. Annu Rev Cell Biol. 1992;8:67–113. doi: 10.1146/annurev.cb.08.110192.000435. [DOI] [PubMed] [Google Scholar]
  8. Hopfner K. P., Karcher A., Shin D. S., Craig L., Arthur L. M., Carney J. P., Tainer J. A. Structural biology of Rad50 ATPase: ATP-driven conformational control in DNA double-strand break repair and the ABC-ATPase superfamily. Cell. 2000 Jun 23;101(7):789–800. doi: 10.1016/s0092-8674(00)80890-9. [DOI] [PubMed] [Google Scholar]
  9. Hung L. W., Wang I. X., Nikaido K., Liu P. Q., Ames G. F., Kim S. H. Crystal structure of the ATP-binding subunit of an ABC transporter. Nature. 1998 Dec 17;396(6712):703–707. doi: 10.1038/25393. [DOI] [PubMed] [Google Scholar]
  10. Jones P. M., George A. M. Subunit interactions in ABC transporters: towards a functional architecture. FEMS Microbiol Lett. 1999 Oct 15;179(2):187–202. doi: 10.1111/j.1574-6968.1999.tb08727.x. [DOI] [PubMed] [Google Scholar]
  11. Klein I., Sarkadi B., Váradi A. An inventory of the human ABC proteins. Biochim Biophys Acta. 1999 Dec 6;1461(2):237–262. doi: 10.1016/s0005-2736(99)00161-3. [DOI] [PubMed] [Google Scholar]
  12. Loo T. W., Clarke D. M. The transmembrane domains of the human multidrug resistance P-glycoprotein are sufficient to mediate drug binding and trafficking to the cell surface. J Biol Chem. 1999 Aug 27;274(35):24759–24765. doi: 10.1074/jbc.274.35.24759. [DOI] [PubMed] [Google Scholar]
  13. Rosenberg M. F., Callaghan R., Ford R. C., Higgins C. F. Structure of the multidrug resistance P-glycoprotein to 2.5 nm resolution determined by electron microscopy and image analysis. J Biol Chem. 1997 Apr 18;272(16):10685–10694. doi: 10.1074/jbc.272.16.10685. [DOI] [PubMed] [Google Scholar]
  14. Sankaran B., Bhagat S., Senior A. E. Inhibition of P-glycoprotein ATPase activity by beryllium fluoride. Biochemistry. 1997 Jun 3;36(22):6847–6853. doi: 10.1021/bi970034s. [DOI] [PubMed] [Google Scholar]
  15. Sankaran B., Bhagat S., Senior A. E. Inhibition of P-glycoprotein ATPase activity by procedures involving trapping of nucleotide in catalytic sites. Arch Biochem Biophys. 1997 May 1;341(1):160–169. doi: 10.1006/abbi.1997.9944. [DOI] [PubMed] [Google Scholar]
  16. Sarkadi B., Price E. M., Boucher R. C., Germann U. A., Scarborough G. A. Expression of the human multidrug resistance cDNA in insect cells generates a high activity drug-stimulated membrane ATPase. J Biol Chem. 1992 Mar 5;267(7):4854–4858. [PubMed] [Google Scholar]
  17. Schmees G., Stein A., Hunke S., Landmesser H., Schneider E. Functional consequences of mutations in the conserved 'signature sequence' of the ATP-binding-cassette protein MalK. Eur J Biochem. 1999 Dec;266(2):420–430. doi: 10.1046/j.1432-1327.1999.00871.x. [DOI] [PubMed] [Google Scholar]
  18. Senior A. E., al-Shawi M. K., Urbatsch I. L. The catalytic cycle of P-glycoprotein. FEBS Lett. 1995 Dec 27;377(3):285–289. doi: 10.1016/0014-5793(95)01345-8. [DOI] [PubMed] [Google Scholar]
  19. Shepard R. L., Winter M. A., Hsaio S. C., Pearce H. L., Beck W. T., Dantzig A. H. Effect of modulators on the ATPase activity and vanadate nucleotide trapping of human P-glycoprotein. Biochem Pharmacol. 1998 Sep 15;56(6):719–727. doi: 10.1016/s0006-2952(98)00212-3. [DOI] [PubMed] [Google Scholar]
  20. Szabó K., Welker E., Bakos, Müller M., Roninson I., Váradi A., Sarkadi B. Drug-stimulated nucleotide trapping in the human multidrug transporter MDR1. Cooperation of the nucleotide binding domains. J Biol Chem. 1998 Apr 24;273(17):10132–10138. doi: 10.1074/jbc.273.17.10132. [DOI] [PubMed] [Google Scholar]
  21. Szakács G., Ozvegy C., Bakos E., Sarkadi B., Váradi A. Transition-state formation in ATPase-negative mutants of human MDR1 protein. Biochem Biophys Res Commun. 2000 Oct 5;276(3):1314–1319. doi: 10.1006/bbrc.2000.3576. [DOI] [PubMed] [Google Scholar]
  22. Urbatsch I. L., Sankaran B., Bhagat S., Senior A. E. Both P-glycoprotein nucleotide-binding sites are catalytically active. J Biol Chem. 1995 Nov 10;270(45):26956–26961. doi: 10.1074/jbc.270.45.26956. [DOI] [PubMed] [Google Scholar]
  23. Urbatsch I. L., Sankaran B., Weber J., Senior A. E. P-glycoprotein is stably inhibited by vanadate-induced trapping of nucleotide at a single catalytic site. J Biol Chem. 1995 Aug 18;270(33):19383–19390. doi: 10.1074/jbc.270.33.19383. [DOI] [PubMed] [Google Scholar]

Articles from Biochemical Journal are provided here courtesy of The Biochemical Society

RESOURCES